Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer’s disease (AD) via protein modification and immunotherapy-based solutions. Alzinova’s novel AβCC Peptide Technology is designed to target neurotoxic proteins with immunotherapy. The company’s pipeline consists of two oligomer-targeting immunotherapies – ALZ-101 (approaching Phase II) and ALZ-201 (preclinical) – with the latter being a more specific, preclinical-stage revision of ALZ-101. Phase Ib clinical trial results for ALZ-101 have shown good safety and tolerability and exploratory analysis of the efficacy of the drug exceeded expectations. ALZ-101 has been submitted for a Phase II clinical study seeking further evidence of the drug’s efficacy as an AD treatment in a larger patient group.
LÄS MER
